Results 71 to 80 of about 26,123,489 (353)

Prevalence of human filovirus infections in sub-Saharan Africa: A systematic review and meta-analysis protocol

Systematic Reviews
Background Recent outbreaks of Ebola virus disease (EVD) and Marburg virus disease (MVD) in sub-Saharan Africa illustrate the need to better understand animal reservoirs, burden of disease, and human transmission of filoviruses.
Christopher S. Semancik, Christopher L. Cooper, Thomas S. Postler, Matt Price, Heejin Yun, Marija Zaric, Monica Kuteesa, Nina Malkevich, Andrew Kilianski, Swati B. Gupta, Suzanna C. Francis   +10 more
doaj   +1 more source

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trialsResearch in context

EBioMedicine
Summary: Background: Lassa fever (LF) is a zoonotic haemorrhagic disease caused by Lassa virus (LASV), which is endemic in West African countries. The multimammate rat is the main animal reservoir and its geographic range is expected to expand due to ...
Christopher L. Cooper, Gavin Morrow, Maoli Yuan, Thomas S. Postler, Maxwell L. Neal, Robert W. Cross, Courtney Woolsey, Krystle N. Agans, Viktoriya Borisevich, Ryan P. McNamara, Caroline Atyeo, Vicky Roy, Daritza Germosen, Fuxiang Hou, Shui L. Li, Lucia Reiserova, Yesle Choi, Aaron Wilson, Denise Wagner, Olivia Wallace-Selman, Alexei Carpov, Fuqiang Geng, Deborah J. Frederick, Joanne DeStefano, Anne M. Ercolini, Adrian S. Enriquez, Kathryn M. Hastie, Suzane Ramos da Silva, Eddy Sayeed, John W. Coleman, Andrew Kilianski, Galit Alter, Erica Ollmann Saphire, John D. Aitchison, Thomas W. Geisbert, Swati B. Gupta, Mark B. Feinberg, Christopher L. Parks   +37 more
doaj   +1 more source

Selection and characterization of vaccine strain for Enterovirus 71 vaccine development

, 2012
[[abstract]]Enterovirus 71 (EV71) has recently emerged as an important neurotropic virus in Asia because effective medications and prophylactic vaccine against EV71 infection are not available.
Chang, JY;Chang, CP;Tsai, HH;Lee, CD;Lian, WC;Ih Jen, S;Sai, IH;Liu, CC;Chou, AH;Lu, YJ;Chen, CY;Lee, PH;Chiang, JR;Chong, PC
core   +1 more source

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source

Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses

Immunity, Inflammation and Disease
Background Messenger RNA (mRNA) vaccines emerged as a powerful tool in the fight against infections. Unlike traditional vaccines, this unique type of vaccine elicits robust and persistent innate and humoral immune response with a unique host cell ...
Elijah K. Oladipo, Olanrewaju D. Oyelakin, Abdulsamad O. Aiyelabegan, Elizabeth O. Olajide, Victoria O. Olatayo, Kaothar P. Owolabi, Yewande B. Shittu, Rhoda O. Olugbodi, Hezekiah A. Ajala, Raji A. Rukayat, Deborah O. Olayiwola, Boluwatife A. Irewolede, Esther M. Jimah, Julius K. Oloke, Taiwo O. Ojo, Olumide F. Ajani, Bamidele A. Iwalokun, Olatunji M. Kolawole, Olumuyiwa E. Ariyo, Daniel A. Adediran, Seun E. Olufemi, Helen Onyeaka   +21 more
doaj   +1 more source

Systems biology in vaccine design [PDF]

Microbial Biotechnology, 2011
Summary Vaccines are the most effective tools to prevent infectious diseases and to minimize their impact on humans or animals. Despite the successful development of vaccines that are able to elicit potent and protective immune responses, the majority of vaccines have been so far developed empirically and ...
Six, Adrien, Bellier, Bertrand, Thomas‐Vaslin, Véronique, Klatzmann, David   +3 more
openaire   +2 more sources

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. [PDF]

, 2012
OBJECTIVE: To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.
Edmunds, W. John, van Hoek, Albert Jan, Trotter, Caroline L, Rozenbaum, Mark H., C. L. Trotter, Miller, Elizabeth, Rozenbaum, Mark H, D. Fleming, Trotter, Caroline L., E. Miller, M. H. Rozenbaum, Edmunds, W John, W. J. Edmunds, Fleming, Douglas, A. J. van Hoek   +14 more
core   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. [PDF]

, 2011
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.\ud \ud METHODS\ud \ud From March 2009 through January 2011, we enrolled 15,460 ...
Machera, Francisca, Abdulla, Salim, Sillman, Marla, Maingi, Charity, Aide, Pedro, Kremsner, Peter Gottfried, Conzelmann, Cornelia, Adjei, George, Abdul, Omari, Leach, Amanda, Methogo, Barbara Gaelle Nfono Ondo, Bejon, Philip, Gondi, Stacey, Chome, Nelecy, Doucka, Yannick, Aponte, John J, Guerra, Yolanda, Chandramohan, Daniel, null null, Jones, David, Liheluka, Edwin, Loucq, Christian, Omoto, Jackton, Nyakuipa, Dalitso, Flamen, Arnaud, Jongert, Erik, Otieno, Walter, Bassat, Quique, Mordmüller, Benjamin, Slutsker, Laurence, Agyekum, Alex, Ofori-Anyinam, Opokua, Hamad, Ali Said, Wasuna, Ruth, Vansadia, Preeti, Lanaspa, Miguel, Drakeley, Chris, Kaboré, William, Asante, Isaac, Gesase, Samwel, Cohen, Joe, Shubis, Kafuruki, Ogutu, Bernhards, Agnandji, Selidji Todagbe, Otieno, Lucas, Sambian, David, Ansong, Daniel, Lell, Bertrand, Awino, Norbert, Gitaka, Jesse, Carter, Terrell, Juma, Omar, Shomari, Mwanajaa, Hoffman, Irving, Mtoro, Ali, Schellenberg, David, Quelhas, Diana, Radford, Afiya, Minja, Rose, Kerubo, Christine, Theander, Thor, Ahmed, Saumu, Odero, Chris, Vekemans, Johan, Nkomo, Ruthendo, Muturi-Kioi, Vincent, Mvalo, Tisungane, RTS,S Clinical Trials Partnership, Tsofa, Benjamin, Dosoo, David, Ouédraogo, Jean Bosco, Mwangoka, Grace, Rettig, Theresa, Sorgho, Hermann, Ouédraogo, Sayouba, Osei-Kwakye, Kingsley, Agbenyega, Tsiri, Owira, Victorine, Issifou, Saadou, Kariuki, Simon, Oneko, Martina, Otieno, Kephas, Olotu, Ally, Lapierre, Didier, Fernandes, José Francisco, Ali, Ali Mohammed, Boahen, Owusu, Onyango, Agnes Akoth, Sylverken, Justice, Hamel, Mary J, Macete, Eusébio, Asante, Kwaku Poku, Owusu-Agyei, Seth, Lemnge, Martha, Ayamba, Samuel, Msika, Albans, Kayan, Kingsley, Alonso, Pedro, Kamthunzi, Portia, Otieno, Allan, Ballou, W Ripley, Nekoye, Otsyula, Lievens, Marc, Abossolo, Béatrice Peggy, Mandjate, Sofia, Marsh, Kevin, Urassa, Alwisa Martin, Mahende, Coline, Bawa, John, Sandrine, Yara, Akoo, Pauline, Adjei, Samuel, Njuguna, Patricia, Jumbe, Allan, Williamson, John, Leboulleux, Didier, Greenwood, Brian, Malabeja, Anangisye, Chilengi, Roma, Nhamuave, Arlindo, Guiguemdé, Robert Tinga, Tinto, Halidou, Tahita, Marc Christian, Martinson, Francis, Kilavo, Hassan, Lusingu, John, Boateng, Harry Owusu, Chintedza, Joseph, Soulanoudjingar, Solange Solmeheim, Lang, Trudie, Sacarlal, Jahit, Bruls, Myriam, The RTS, S. Clinical Trials Partnership, Sykes, Alma, Owusu, Larko, Tanner, Marcel, Laserson, Kayla F, Peshu, Norbert, Savarese, Barbara, Owusu-Ofori, Ruth, Valea, Innocent, D'Alessandro, Umberto, Salim, Nahya   +142 more
core   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source